Price to Earnings (P/E)
since 2005
Calculation
Allergan PLC, P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss) attributable to ordinary shareholders1 (in thousands) | ÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2020 | — | = | 198.00 | ÷ | -16.02 | -16.02 | = | -5,271,000 | ÷ | 329,002,015 | |
| Feb 15, 2019 | — | = | 139.07 | ÷ | -15.46 | -15.46 | = | -5,142,800 | ÷ | 332,614,474 | |
| Feb 16, 2018 | — | = | 164.04 | ÷ | -13.33 | -13.33 | = | -4,403,900 | ÷ | 330,320,420 | |
| Feb 24, 2017 | 5.60 | = | 245.37 | ÷ | 43.84 | 43.84 | = | 14,695,000 | ÷ | 335,224,713 | |
| Feb 26, 2016 | 31.94 | = | 298.07 | ÷ | 9.33 | 9.33 | = | 3,683,200 | ÷ | 394,687,384 | |
| Feb 18, 2015 | — | = | 284.00 | ÷ | -6.12 | -6.12 | = | -1,630,500 | ÷ | 266,252,295 | |
| Feb 25, 2014 | — | = | 225.00 | ÷ | -4.31 | -4.31 | = | -750,400 | ÷ | 174,199,744 | |
| Feb 28, 2013 | 111.88 | = | 85.16 | ÷ | 0.76 | 0.76 | = | 97,300 | ÷ | 127,832,241 | |
| Feb 16, 2012 | 29.40 | = | 60.31 | ÷ | 2.05 | 2.05 | = | 260,900 | ÷ | 127,165,346 | |
| Feb 22, 2011 | 37.46 | = | 54.90 | ÷ | 1.47 | 1.47 | = | 184,400 | ÷ | 125,827,379 | |
| Mar 1, 2010 | 22.32 | = | 40.12 | ÷ | 1.80 | 1.80 | = | 222,000 | ÷ | 123,516,219 | |
| Feb 23, 2009 | 12.77 | = | 29.10 | ÷ | 2.28 | 2.28 | = | 238,379 | ÷ | 104,627,327 | |
| Feb 25, 2008 | 20.72 | = | 28.19 | ÷ | 1.36 | 1.36 | = | 141,030 | ÷ | 103,657,619 | |
| Mar 1, 2007 | — | = | 25.71 | ÷ | -4.34 | -4.34 | = | -445,005 | ÷ | 102,500,489 | |
| Mar 10, 2006 | 23.73 | = | 29.55 | ÷ | 1.25 | 1.25 | = | 138,233 | ÷ | 111,029,721 |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Allergan PLC Annual Report.
- Share Price Trend
- The share price exhibited a generally upward trajectory from 2006 through 2016, beginning at $29.55 and peaking at $298.07 in 2016. This represents a substantial increase over the 10-year span. Notably, after reaching this high point, the share price declined to $164.04 by 2018 and further to $139.07 in 2019. However, there was a recovery observed in 2020 with a price increase to $198. Overall, the share price shows a trend of growth interrupted by significant volatility in the later years.
- Earnings Per Share (EPS) Trend
- EPS values fluctuate considerably over the period with alternating positive and negative outcomes. 2006 saw a positive EPS of $1.25 which dropped sharply to a negative $-4.34 in 2007. Positive recovery occurred intermittently with values such as $2.28 in 2009 and $9.33 in 2016, and a remarkable spike to $43.84 in 2017. However, the years following 2017 show a steep decline, with negative EPS values of $-13.33, $-15.46, and $-16.02 from 2018 to 2020 respectively. This volatility suggests inconsistent profitability or possibly one-time events impacting earnings.
- Price-to-Earnings (P/E) Ratio Analysis
- The P/E ratio fluctuates in line with the variable EPS and share price data. Starting at 23.73 in 2006, the P/E ratio experienced significant increases and decreases, with values like 20.72 in 2008, a marked spike of 111.88 in 2013, and a decline to 5.6 in 2017. The ratio was missing for some years, likely due to negative earnings making the metric undefined or meaningless. The large fluctuations reflect the volatility in earnings and share price, indicating changing market expectations and perceptions of growth and risk.
- Summary of Financial Patterns
- The data reflects a company undergoing periods of strong market valuation growth alongside marked volatility in earnings. The high share prices and occasional large P/E ratios suggest times of investor optimism, whereas the sharp declines in EPS accompanied by missing P/E data in later years indicate operational challenges or extraordinary financial events impacting profitability. Overall, the trends point to cyclical earnings performance with a growth trend in share price that is punctuated by considerable fluctuations in profitability.
Comparison to Competitors
Allergan PLC, P/E, long-term trends, comparison to competitors
| Allergan PLC | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2020 | — | 17.82 | 17.07 | 41.99 | 38.34 | 16.19 | 16.45 | 25.99 | 20.60 | 11.63 | 19.86 | 33.36 | 52.90 |
| Feb 15, 2019 | — | 20.60 | 14.01 | 16.81 | 29.77 | 39.13 | 15.26 | 23.74 | 33.46 | 21.58 | 18.17 | 35.19 | 22.59 |
| Feb 16, 2018 | — | 35.47 | 64.06 | 103.55 | 27.25 | — | 22.75 | 268.10 | 61.63 | 9.99 | 28.99 | 37.66 | 155.08 |
| Feb 24, 2017 | 5.60 | 16.54 | 16.03 | 20.56 | 23.02 | 32.39 | 6.83 | 20.08 | 46.14 | 28.10 | 42.64 | 30.45 | — |
| Feb 26, 2016 | 31.94 | 17.01 | 15.95 | 64.22 | 17.85 | 33.35 | 6.75 | 18.80 | 31.64 | 26.37 | 60.50 | 26.19 | — |
| Feb 18, 2015 | — | 55.08 | 22.96 | 49.80 | 23.69 | 33.06 | 12.85 | 17.15 | 13.94 | 23.03 | 118.44 | 27.26 | — |
| Feb 25, 2014 | — | 19.64 | 18.69 | 35.01 | 19.74 | 13.88 | 42.00 | 18.72 | 37.83 | 9.32 | 77.00 | 38.43 | — |
| Feb 28, 2013 | 111.88 | 11.51 | 15.68 | 30.56 | 17.73 | 14.99 | 25.20 | 19.64 | 20.94 | 13.51 | 21.42 | 22.54 | — |
| Feb 16, 2012 | 29.40 | — | 14.61 | 15.07 | 16.92 | 10.42 | 12.20 | 18.48 | 18.63 | 15.99 | — | 15.58 | 267.42 |
| Feb 22, 2011 | 37.46 | — | 10.53 | 13.99 | 18.29 | 7.86 | 10.68 | 12.23 | 116.63 | 18.63 | — | 20.87 | — |
| Mar 1, 2010 | 22.32 | — | 12.10 | 4.03 | 20.93 | 9.18 | 16.29 | 14.22 | 9.00 | 16.41 | — | 23.49 | — |
| Feb 23, 2009 | 12.77 | — | 12.06 | 7.68 | 12.56 | — | 20.29 | 11.67 | 6.53 | 10.25 | — | 15.25 | — |
| Feb 25, 2008 | 20.72 | — | 15.64 | 20.60 | 17.35 | 19.26 | 25.19 | 17.07 | 29.88 | 18.51 | — | 30.76 | — |
| Mar 1, 2007 | — | — | 25.43 | 34.64 | 19.65 | 22.40 | — | 17.02 | 21.57 | 9.18 | — | 113.28 | — |
| Mar 10, 2006 | 23.73 | — | 23.70 | 14.96 | 21.38 | 31.90 | 34.15 | 16.95 | 16.62 | 23.92 | — | 25.36 | — |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Allergan PLC, P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Allergan PLC | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 18, 2020 | — | 21.03 |
| Feb 15, 2019 | — | 22.89 |
| Feb 16, 2018 | — | 35.21 |
| Feb 24, 2017 | 5.60 | 20.62 |
| Feb 26, 2016 | 31.94 | 19.37 |
| Feb 18, 2015 | — | 21.40 |
| Feb 25, 2014 | — | 19.54 |
| Feb 28, 2013 | 111.88 | 17.56 |
| Feb 16, 2012 | 29.40 | 16.42 |
| Feb 22, 2011 | 37.46 | 16.11 |
| Mar 1, 2010 | 22.32 | 11.66 |
| Feb 23, 2009 | 12.77 | 12.21 |
| Feb 25, 2008 | 20.72 | 20.04 |
| Mar 1, 2007 | — | 17.46 |
| Mar 10, 2006 | 23.73 | 20.94 |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Allergan PLC, P/E, long-term trends, comparison to industry (health care)
| Allergan PLC | Health Care | |
|---|---|---|
| Feb 18, 2020 | — | 21.64 |
| Feb 15, 2019 | — | 25.29 |
| Feb 16, 2018 | — | 30.93 |
| Feb 24, 2017 | 5.60 | 21.47 |
| Feb 26, 2016 | 31.94 | 19.50 |
| Feb 18, 2015 | — | 21.56 |
| Feb 25, 2014 | — | 18.62 |
| Feb 28, 2013 | 111.88 | 15.80 |
| Feb 16, 2012 | 29.40 | 15.84 |
| Feb 22, 2011 | 37.46 | 15.00 |
| Mar 1, 2010 | 22.32 | 11.75 |
| Feb 23, 2009 | 12.77 | 12.99 |
| Feb 25, 2008 | 20.72 | 19.44 |
| Mar 1, 2007 | — | 18.63 |
| Mar 10, 2006 | 23.73 | 21.68 |
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).